Engineered oncolytic virus armed w immune-stimulating transgenes for patients w solid tumors. Ph 1 and Ph 1/2 trials ongoing with multiple data readouts in 2018 and 2019. CMO developed Yervoy at BMS.
Phase l or ll
Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Oncology
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Clients at Jefferies
New York, NY, United States,
June 4 –
June 7, 2019
European Biotech Investor Day 2019
New York City,
August 1, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by